Potential restoration of HDL function with apolipoprotein A-I mimetic peptide in end-stage renal disease.
High-density lipoprotein (HDL) cholesterol level is low in dialysis patients. The HDL that is present is dysfunctional, failing to protect low-density lipoprotein (LDL) from oxidation and reduce levels of oxidized LDL. Addition of the orally absorbable amphipathic peptide 4-F to LDL obtained from dialysis patients protects LDL from oxidation in vitro and reduces the capacity of oxidized LDL to induce expression of monocyte chemoattractant protein-1 (MCP-1) by vascular endothelial function in culture, potentially providing a tool to reduce cardiovascular risk in dialysis patients.
Kaysen
George A
GA
Division of Nephrology, Department of Medicine, University of California, Davis, Davis, California 95616, USA. gakaysen@ucdavis.edu
D016632:Apolipoprotein A-I / Q000737:chemistry*; D008076:Cholesterol, HDL / Q000502:physiology*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008075:Lipoproteins, HDL / Q000502:physiology; D018716:Molecular Mimicry; D010455:Peptides / Q000627:therapeutic use*
D016632:Apolipoprotein A-I; D008076:Cholesterol, HDL; D008075:Lipoproteins, HDL; D010455:Peptides